L
Lee Goldman
Researcher at Harvard University
Publications - 194
Citations - 27928
Lee Goldman is an academic researcher from Harvard University. The author has contributed to research in topics: Cost effectiveness & Myocardial infarction. The author has an hindex of 79, co-authored 191 publications receiving 27129 citations. Previous affiliations of Lee Goldman include University of California, Berkeley & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Long-term impact of smoking cessation on the incidence of coronary heart disease.
TL;DR: It is concluded that smoking reductions will markedly reduce coronary heart disease, especially in younger age groups, and that this benefit will be slightly offset by a small increase in absolute incidence in elderly men.
Prediction of Visual Function After Cataract Surgery
Carol M. Mangione,E. John Orav,Mary G. Lawrence,Russell S. Phillips,Johanna M. Seddon,Lee Goldman +5 more
TL;DR: Preoperative data can identify patients who are likely to have improvements in visual function after cataract surgery, and such findings may be useful in the selection of patients for this high-volume procedure.
Journal ArticleDOI
Modernizing the paths to certification in internal medicine and its subspecialties
TL;DR: The current approach to training and certification in internal medicine can be compared metaphorically with ell maturation, where trainees remain pluripotent stem cells or 3 years before either failing to differentiate, and hereby remaining as internists only, or differentiating nto subspecialists.
Journal ArticleDOI
Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Nathalie Moise,Chen Huang,Anthony Rodgers,Ciaran N Kohli-Lynch,Keane Y. Tzong,Pamela G. Coxson,Kirsten Bibbins-Domingo,Lee Goldman,Andrew E. Moran +8 more
TL;DR: Among patients aged 35 to 74 years, adding intensive blood pressure goals for high-risk groups to current national hypertension treatment guidelines prevents additional CVD deaths while saving costs provided that medication costs are controlled.